EUVIMED · CrossrefJournal
Chinese Clinical Oncology
ISSN 2304-3865 · AME Publishing Company
Latest articles
Epidemiology, diagnosis, and treatment of primary pulmonary mucosa-associated lymphoid tissue lymphoma
Network pharmacology of Sijunzi decoction in pancreatic cancer
Age, endocrine therapy persistence, and recurrence risk in hormone receptor-positive early breast cancer: clarifying a long-standing clinical question
Drug-induced liver injury and acute pancreatitis during trastuzumab therapy in a BRCA1-mutated, HER2-positive breast cancer patient: a case report
Can recurrence-free survival replace overall survival for resectable esophageal cancer?
Adjuvant CDK4/6 inhibitors and novel therapies in early breast cancer: lessons from monarchE overall survival data
Venetoclax with intensive chemotherapy in acute myeloid leukemia
Optimizing media composition for patient-derived organoids in ovarian cancer: a narrative review
Combination therapy in sarcomas and the challenges of heterogeneity
Toxicity management in thoracic chemoradioimmunotherapy: pirfenidone for low grade pneumonitis and lung fibrosis
Back to the future: “7+3” joins the venetoclax plus intensive chemotherapy movement
Clonal hematopoiesis in breast cancer: moving beyond prevalence toward clinical relevance
Differentiating glioma recurrence from radiation necrosis: a narrative review of positron emission tomography and magnetic resonance imaging and their diagnostic accuracies
Biliary neuroendocrine tumors: a narrative review of current diagnostics and management strategies
Role of androgen receptor signaling in chemoresistance in urothelial cancer: a narrative review
Hormone therapy in younger women: reassessing risk narratives in the era of precision menopausal care
First-line programmed death-1 blockade plus chemotherapy in low programmed cell death ligand 1 esophageal squamous cell carcinoma: beyond a single biomarker
Claudin 18.2 testing in gastroesophageal and pancreatobiliary cancers: current status, clinical implications and challenges
First-line fulvestrant vs. anastrozole in hormone receptor-positive advanced breast cancer: insights from the final FALCON trial results
Fos-related antigen 1 is required for Helicobacter pylori-induced inflammatory response in gastric epithelial cells through NF-κB pathway
Targeting metabolism in acute myeloid leukemia: the next therapeutic frontier?
Advances and applications of liquid biopsy approaches in hepatopancreatobiliary (HPB) cancers: a literature review
Is rechallenge with CDK4/6 inhibitors beyond progression reasonable for patients with hormone receptor-positive and HER2-negative advanced breast cancer?—a commentary on the PALMIRA trial
TP63 drives TKI resistance in EGFR-mutant lung cancer via ferroptosis inhibition
Short- and long-term outcomes after laparoscopic versus open total gastrectomy for stage 0–I gastric cancer: a multicenter, retrospective analysis
Advancing precision oncology through innovative and adaptive master protocol designs: statistical, operational, and regulatory perspectives
Eribulin and trastuzumab in early-line HER2-positive metastatic breast cancer: evaluating an active chemotherapy partner in an evolving treatment landscape
Impact of neoadjuvant chemotherapy vs. upfront surgery on survival in early-onset colorectal cancer—a single centre experience
A narrative review of the value of immunoinflammatory markers in the prognosis of endometrial carcinoma
Benign metastasizing leiomyoma: a systematic review of diagnosis, management, and outcomes
EUVIMED